Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Eosinophilic Esophagitis (EoE): full-pipeline trial registry
5 of 11 indexed Eosinophilic Esophagitis (EoE) trials are currently recruiting.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Eosinophilic Esophagitis (EoE): 11 US clinical trials tracked, 5 recruiting.
Eosinophilic Esophagitis (EoE) is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition eosinophilic-esophagitis-eoe
OPEN 5 | RECR 45% | LATE 4 | EARLY 3 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)
Eosinophilic Esophagitis (EoE) lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Eosinophilic Esophagitis (EoE) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Eosinophilic Esophagitis (EoE) recruits in line with its size-band peers.
5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Eosinophilic Esophagitis (EoE) research.
Regeneron Pharmaceuticals accounts for 3 of 11 trials (27.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Eosinophilic Esophagitis (EoE) enrolment sits around 93 participants.
Median target enrolment is 93 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.
-
Eosinophilic Esophagitis (EoE) splits between interventional and observational designs.
7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Regeneron Pharmaceuticals
NCT06693531
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
Children's Hospital of Philadelphia
NCT06389994
Surface EMG Testing on Swallowing in EoE Patients
Mayo Clinic
NCT07156357
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
University of California, San Diego
NCT06665971
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Regeneron Pharmaceuticals
NCT07112378
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Uniquity One (UNI)
NCT06598462
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
Shire
NCT02736409
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
Children's Hospital Medical Center, Cincinnati
NCT02778867
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals
NCT04394351
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
Shire
NCT01642212
Eating With Eosinophilic Esophagitis (EoE)
Mayo Clinic
NCT03581838
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Eosinophilic Esophagitis (EoE) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Eosinophilic Esophagitis (EoE) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Eosinophilic Esophagitis (EoE) page
11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Eosinophilic Esophagitis (EoE) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Eosinophilic Esophagitis (EoE) trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eosinophilic Esophagitis (EoE) condition card totals 11 registered trials; most-linked intervention dupilumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.